These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38460519)

  • 1. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
    Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
    Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
    Kaneko MK; Suzuki H; Ohishi T; Nakamura T; Tanaka T; Kato Y
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
    Kaneko MK; Suzuki H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Anti-HER2 Monoclonal Antibody H
    Tateyama N; Asano T; Ohishi T; Takei J; Hosono H; Nanamiya R; Tanaka T; Sano M; Saito M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):184-190. PubMed ID: 34424760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
    Kato Y; Ohishi T; Takei J; Nakamura T; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):135-139. PubMed ID: 32644843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
    Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H
    Kato Y; Ohishi T; Sano M; Asano T; Sayama Y; Takei J; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Jun; 39(3):61-65. PubMed ID: 32423281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
    Kato Y; Ohishi T; Takei J; Nakamura T; Sano M; Asano T; Sayama Y; Hosono H; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):123-128. PubMed ID: 32552424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of H
    Yamada S; Itai S; Nakamura T; Chang YW; Harada H; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):287-290. PubMed ID: 29172998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer.
    Kaneko MK; Yamada S; Itai S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):59-62. PubMed ID: 29315012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Novel Anti-HER2 Monoclonal Antibody H
    Takei J; Asano T; Tanaka T; Sano M; Hosono H; Nanamiya R; Tateyama N; Saito M; Suzuki H; Harada H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):168-176. PubMed ID: 34424764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defucosylated Monoclonal Antibody (H
    Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H
    Itai S; Fujii Y; Kaneko MK; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Takahashi M; Suzuki H; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):143-148. PubMed ID: 28700270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
    Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G
    Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
    Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
    Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
    Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
    Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
    Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
    Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf).
    Suzuki H; Asano T; Ohishi T; Yoshikawa T; Suzuki H; Mizuno T; Tanaka T; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):34-40. PubMed ID: 36383106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.